unknown
Stage
1
Investors
About
Immitra Bio is a spin-off from ETH Zurich developing a next-generation platform for in vivo gene editing to treat rare genetic disorders. The company aims to deliver off-the-shelf, single-injection gene therapies that correct genetic defects directly in the body as an alternative to highly personalized ex vivo approaches.
Explore Immitra Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.